Institution Directory

Clinical trials at City of Hope

Sites in Duarte, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1045

Shown on this page

Current sort

Live official records

Conditions: Multiple Myeloma
Interventions: Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Stichting European Myeloma Network; Network
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 27
States / cities: Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more

Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate, Fludeoxyglucose F-18, IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: Anusha Kalbasi; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Stanford, California

Conditions: AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy; Drug · Procedure · Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years to 66 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more

Conditions: High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions: CBX-250; Drug
Lead sponsor: Crossbow Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Duarte, California • Palo Alto, California • Tampa, Florida + 7 more

Conditions: Mantle Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib, Positron Emission Tomography and Computed Tomography Scan, Rituximab; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Magnetic Resonance Imaging, Obinutuzumab, Venetoclax; Procedure · Other · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Duarte, California • Irvine, California • Long Beach, California + 4 more

Conditions: Gastric Carcinoma
Interventions: Biopsy, Biospecimen Collection, Breath Test, Esophagogastroduodenoscopy, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 40 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer
Interventions: Letrozole, Ribociclib, Placebo; Drug
Lead sponsor: Qamar Khan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 13
States / cities: Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more

Conditions: Lung Carcinoma
Interventions: Educational Intervention, Exercise Intervention, Medical Device Usage and Evaluation, Physical Performance Testing, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Davis, California • Duarte, California • Irvine, California + 13 more

Conditions: Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm, Lung Metastases From Any Primary, Endobronchial Metastases, Colon Cancer, Sarcoma
Interventions: Computed Tomography, Ethiodized Oil, Mitomycin, Transarterial Chemoembolization, Tris-acryl Gelatin Microspheres; Procedure · Drug · Device
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Duarte, California • New York, New York

Conditions: Colorectal Cancer, Bladder Cancer
Interventions: Telehealth Intervention, Standard of care; Behavioral · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Interventions: Health Promotion, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

About this City of Hope institution page

What this page lists: ClinicalTrials.gov records that list City of Hope in Duarte, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at City of Hope

Filter and sort this campus

Live official records

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer

Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

Phase II Trial of Lung Chemoemobolization

Telehealth Intervention for Ostomy Self-Management

A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation

About this City of Hope institution page